The POPLAR and ATLANTIC trails have indicated that anti-PD-1/PD-L1 immunotherapy had lower therapeutic effect on NSCLC patients with EML4-ALK mutation than those with wild type (Fehrenbacher et al. 2016; Garassino et al. 2018). Here, EML4 is linked to non-small cell lung carcinoma.